Potential Risks
The method of convalescent PT has been used daily in many hospitals for
years. Convalescent PT against SARS-Cov-2 differs from standard plasma
only in the presence of neutralizing antibodies directed against
Sars-Cov-2, therefore the transfusion risks could be considered not
different from those of standard plasma. An open question could be the
risk of infection transmission. In COVID-19 patients this should
obviously not be considered because they are already infected, but in
the case of prophylactic use yes. However, these are theoretical risks,
as no transmission of respiratory infection has ever been reported.
viral by plasma transfusion. SARS-CoV-2 is probably not considered a
relevant transfusion virus of infection.(21-22). However, it should be
considered that donors will have to meet certain requirements, such as
waiting a few weeks after the resolution of their symptomatology and
above all must also be negative for SARS-CoV-2, determined by diagnostic
molecular tests.